CHICAGOBUSINESS.COM I JANUARY 15, 2024
AbbVie will lay off megadeals for a while
THE HIGH COST OF CREATING AFFORDABLE HOUSING
Execs predict the acquisitions of Immunogen and Cerevel will help the drugmaker reverse revenue declines by 2025 as Humira fades By Katherine Davis
Inflation, administration fees and a byzantine tax credit system add layers of expenses as the city’s need for affordable housing rises
GEOFFREY BLACK
PAGE 11
After announcing two large acquisitions in as many weeks, AbbVie executives say the drugmaker will take a break from big deals, predicting the company will return to “robust” growth as early as 2025 despite falling sales of its longtime flagship drug, Humira. North Chicago-based AbbVie is paying steep prices for a pair of Boston-area drugmakers. On Nov. 30, the company said it would buy ImmunoGen for $10.1 billion. At $31.26 per share, the buyout price represents a 95% premium to the cancer drug maker’s stock market value before the deal was announced. AbbVie announced on Dec. 6 an $8.7 billion deal to acquire Cerevel Therapeutics for $45 per share, a 73% premium to the neuroscience company’s market price before its stock started rising on takeover talk this week. The deals come as AbbVie has struggled with revenue declines as Humira, its drug approved to treat arthritis and other conditions, began facing biosimilar competition in the U.S. for the first time this year. On an investor call today, CEO Richard Gonzalez said demand for drugs in AbbVie’s current
WHO’S WHO IN CHICAGO BUSINESS 2024
Richard Gonzalez
portfolio, like Skyrizi and Rinvoq, as well as a key drug it will acquire in the ImmunoGen deal, will help drive near-term growth, without giving specific figures. While Cerevel doesn’t yet have any drugs approved, Gonzalez said its “multibillion-dollar” sales opportunity will help support growth into the next decade. “The acquisition of Cerevel, together with the ImmunoGen transaction we announced last week, and our existing assets and pipeline will create one of the most attractive growth portfolios in the industry,” Gonzalez said. “Our near-term prospects are extremely strong. We are positioned to return to robust growth in 2025 and deliver top-tier
Now online at ChicagoBusiness.com/WhosWho2024 Originally published: Dec. 11, 2023
Crain’s exclusive Who’s Who is back with over 400 names you should know. From esteemed chefs to lawyers, real estate magnates to educators, philanthropists to entrepreneurs and everyone in between. VOL. 47, NO. 2 l COPYRIGHT 2024 CRAIN COMMUNICATIONS INC. l ALL RIGHTS RESERVED
RICH GETTING RICHER IN ILLINOIS New tax data show a massive surge in those earning more than $500,000. PAGE 3
See ABBVIE on Page 19
BOOTH INSIGHTS Building a winning culture should be a key part of your intentional business strategy. PAGE 7